STOCK TITAN

Bioxytran, Inc. - $BIXT STOCK NEWS

Welcome to our dedicated page for Bioxytran news (Ticker: $BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bioxytran's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bioxytran's position in the market.

Rhea-AI Summary
Bioxytran, Inc. (BIXT) announces a preprint in ResearchGate showing 50% lesion clearance and regression of Herpes Zoster Neuralgia within 48-72 hours using a topical Galectin-3 antagonist. The company aims to develop oral and intravenous drugs to treat viral diseases, highlighting the potential of this new therapy in managing shingles outbreaks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Summary
Bioxytran, Inc. (BIXT) announces the first patients treated with ProLectin-M in a dose optimization trial to develop an antiviral drug made of sugars. The drug shows promise as a treatment for COVID-19 and other upper respiratory infections. The company plans to conduct a Phase 3 trial in India and additional studies in the US. ProLectin-M has shown high efficacy in previous clinical trials, with potential broad-spectrum antiviral capabilities. The drug targets a new binding region on virus spike proteins, offering a novel approach to viral neutralization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.9%
Tags
clinical trial covid-19
-
Rhea-AI Summary
Bioxytran, a clinical stage biotechnology company, has announced that its patent application for lectin-binding carbohydrates to treat viral infections has been published by the US Patent and Trademark Office. The pending patent covers the use of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses. This patent represents a new direction in antiviral therapies and has potentially wide-reaching implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
Rhea-AI Summary
Bioxytran, Inc. announced that its CCO will present the company's small pharma strategy at the Emerging Growth Conference on October 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.47%
Tags
-
Rhea-AI Summary
BIOXYTRAN, INC. announces significant reduction of viral load in COVID-19, influenza, and RSV in preprint article
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.05%
Tags
none
-
Rhea-AI Summary
Bioxytran receives FDA clearance for clinical trials of ProLectin-M for COVID-19 treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.6%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.79%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.69%
Tags
none
Bioxytran, Inc.

OTC:BIXT

BIXT Rankings

BIXT Stock Data

19.48M
47.16M
59.59%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Newton Upper Falls